At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
Several cell therapy presentations will vie for attention at Ash, though today the spotlight falls on Autolus.
Crispr follows Allogene with backing for off-the-shelf Car-T therapy – and adds big concerns over lack of durability.
Little is known about yesterday’s clinical hold on Allogene’s entire pipeline, but chromosomal abnormalities hint at a worst-case scenario.
Curiously, the $900m acquisition will not include many of Teneobio’s pipeline projects.
The company overhauls senior management as its lead technology continues being passed from pillar to post. What is going on?
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
With many of the usual targets on display Fate, Celyad, Allovir and others look to maintain momentum.